This Sacral Nerve Stimulation (SNS) Market report helps to identify trends in consumer and supply chain dynamics and accordingly interpret marketing, promotional and sales strategies for business growth and an utmost success. This market report aids in developing a successful marketing strategy for your business. Sacral Nerve Stimulation (SNS) Market report has been prepared based on detailed market analysis with inputs from industry experts. It includes historic data, present market trends, environment, technological innovation, upcoming technologies and the technical progress in the related industry. Sacral Nerve Stimulation (SNS) Market research report gives you maximum benefits to grow your business.

Get Sample Analysis of Global Market Information: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-sacral-nerve-stimulation-sns-market

Market Analysis: Global Sacral Nerve Stimulation (SNS) Market

Global sacral nerve stimulation (SNS) market is expected to rise to an estimated value of USD 2385.86 million by 2026, registering a healthy CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the widespread prevalence of urge incontinence in patients globally, along with the increasing volume of patients suffering from overactive bladder.

Key Market Competitors:

Few of the major competitors currently working in the global sacral nerve stimulation (SNS) market are Medtronic; LABORIE; Stimwave LLC; SunMed; Vygon SA; Medline Industries, Inc.; NeuroMetrix, Inc.; SPR Therapeutics; NeuroSigma, Inc.; Abbott; LivaNova PLC; Nuvectra, Axonics Modulation Technologies Inc among others.

Market Definition: Global Sacral Nerve Stimulation (SNS) Market

Sacral nerve stimulation, also known as sacral neuromodulation is a type of electrical nerve stimulation therapy involving implantation of certain stimulators on patients or implanted inside the patient’s body for the treatment of urinary incontinence, fecal incontinence, urge incontinence, chronic anal fissure and others. It provides an effective alternative treatment for the chronic anal fissures in patients who are quite reluctant for invasive surgical interventions.

Market Drivers

Rising incidences of patients suffering from the applicable disorders/conditions of sacral nerve stimulation acts a driver for this market
Growing levels of favorable reimbursement scenarios for sacral nerve stimulation is expected to fuel the market growth
Increasing population relating to geriatric group is also expected to drive the growth of the market
Growing levels of R&D investments undertaken by various manufacturers and authorities for sacral nerve stimulation is expected to boost the growth of the market

Market Restraints

Concerns regarding the negative impacts and side-effects associated with the device is expected to restrict the growth of the market
High costs associated with the device is also expected to hinder the market growth
Lack of technical knowledge and expertise amongst individuals along with the complications associated with the device can also act as a market restraint
Segmentation: Global Sacral Nerve Stimulation (SNS) Market

By Product

Implantable SNS Devices
External SNS Devices

By Type

Electrical Muscle Stimulation
Transcutaneous Electrical Nerve Stimulation

By Application

Urinary & Fecal Incontinence
Urge Incontinence
Chronic Anal Fissure
Others

By End-Users

Hospitals
Clinics
Ambulatory Surgical Centers (ASCs)

By Geography

North America
U.S.
Canada
Mexico
Europe
Germany
Italy
U.K.
France
Spain
Netherlands
Belgium
Switzerland
Turkey
Russia
Rest of Europe
Asia-Pacific
Japan
China
India
South Korea
Australia
Singapore
Malaysia
Thailand
Indonesia
Philippines
Rest of Asia-Pacific
South America
Brazil
Rest of South America
Middle East and Africa
South Africa
Rest of Middle East and Africa

Get TOC of Full Report: https://www.databridgemarketresearch.com/toc/?dbmr=global-sacral-nerve-stimulation-sns-market

Key Developments in the Market:

In January 2019, Nuvectra Corporation announced that the US FDA had extended their conventional 180-day review period for the pre-market approval of Nuvectra’s “Virtis Sacral Neuromodulation (SNM)” system. Although, no additional requirement of information has been suggested by the US FDA, neither have they suggested any deficiencies in the system. Nuvectra is hoping to clarify any additional requests of the US FDA for the timely conclusion of their pre-market approval review
In March 2018, LABORIE announced that they had acquired Cogentix Medical, Inc. for USD 214 million, with the company focusing on specialized innovative therapies for urology field of medical sciences. This acquisition will help in the expansion of current products and technological availability with LABORIE for urology field, especially for overactive bladder and stress urinary incontinence therapies. This acquisition will help the company in providing customers with clinically-effective therapeutic solutions

Competitive Analysis:

Global sacral nerve stimulation (SNS) market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of sacral nerve stimulation (SNS) market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.